WebAug 4, 2024 · The OPTIMA Study is a global, randomized, double-blind, placebo-controlled clinical trial assessing the efficacy of ThermoDox ® in combination with RFA, which was standardized to a minimum of 45 minutes for treating patients with a lesion 3-7 cm in size, versus standardized RFA alone. WebWelcome to OPTIMA, a patient driven clinical study for people with hormone sensitive early breast cancer. OPTIMA aims to improve the way we make decisions about whom we … Taking Part in OPTIMA - OPTIMA OPTIMA Recruiting Sites - OPTIMA The OPTIMA Team - OPTIMA Study Team Contact Details. OPTIMA Trial Team - Warwick Clinical Trials Unit … OPTIMA Protocol v9.0 2024 09 17; OPTIMA Patient flyer v3.0 2024 08 11; OPTIMA … Newsletters - OPTIMA Administering OPTIMA - OPTIMA OPTIMA QRS Staff IS and CF V5.1 10 09 2024; OPTIMA QRS Documentation … OPTIMA Recruitment and Informed Consent Guidance v2.0 2024-03-28; OPTIMA … Publications - OPTIMA
OPTIMA: Optimal Personalised Treatment of early breast …
WebMay 28, 2024 · Methods: OPTIMA is an international academic, partially-blinded RCT of test-directed chemotherapy treatment with an adaptive design. Women and men aged 40 or … WebMar 17, 2015 · Researchers have developed tests to predict who might benefit from having chemotherapy. Prosigna is one of these tests. The Prosigna test uses a specialist … detergent to remove cloth underarm odor
OPTIMA prelim: a randomised feasibility study of personalised …
WebMay 20, 2024 · This issue may be elucidated with the ongoing OPTIMA study, where premenopausal women with breast cancer receive either chemotherapy followed by ET … WebSep 27, 2024 · The OPTIMA Study to date has accumulated data within acceptable safety parameters. ... for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. ... WebJul 13, 2024 · The OPTIMA Study enrolled 554 patients at 65 clinical sites in North America, Europe, China and Asia Pacific. In addition to the primary overall survival endpoint, progression-free survival, time to disease progression, and safety are key secondary endpoints. ... recurrent chest wall breast cancer and non-muscle invading bladder cancers. chunky curtain poles uk